Fluorine in PDB 6n3l: Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents

Enzymatic activity of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents

All present enzymatic activity of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents:
2.7.11.1;

Protein crystallography data

The structure of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents, PDB code: 6n3l was solved by I.D.Hoffman, J.Fujimoto, O.Kurasawa, T.Takagi, M.G.Klein, G.Kefala, S.C.Ding, D.R.Cary, R.Mizojiri, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 25.00 / 2.61
Space group C 2 2 21
Cell size a, b, c (Å), α, β, γ (°) 83.886, 122.233, 120.674, 90.00, 90.00, 90.00
R / Rfree (%) 22.3 / 29

Fluorine Binding Sites:

The binding sites of Fluorine atom in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents (pdb code 6n3l). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total 6 binding sites of Fluorine where determined in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents, PDB code: 6n3l:
Jump to Fluorine binding site number: 1; 2; 3; 4; 5; 6;

Fluorine binding site 1 out of 6 in 6n3l

Go back to Fluorine Binding Sites List in 6n3l
Fluorine binding site 1 out of 6 in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F2501

b:45.4
occ:1.00
F12 A:KAV2501 0.0 45.4 1.0
C11 A:KAV2501 1.4 47.0 1.0
F13 A:KAV2501 2.1 50.1 1.0
F14 A:KAV2501 2.2 50.2 1.0
C8 A:KAV2501 2.4 51.0 1.0
C9 A:KAV2501 3.2 47.1 1.0
C7 A:KAV2501 3.2 46.0 1.0
CD1 A:LEU643 3.3 45.0 1.0
CE A:MET844 3.3 57.9 1.0
CG2 A:ILE839 3.8 52.8 1.0
CD1 A:ILE839 4.0 50.9 1.0
CG2 A:ILE648 4.3 37.1 1.0
CB A:ILE839 4.4 45.2 1.0
C6 A:KAV2501 4.4 51.7 1.0
C10 A:KAV2501 4.4 49.4 1.0
CD1 A:ILE648 4.6 37.2 1.0
SD A:MET844 4.6 64.4 1.0
CG A:LEU643 4.7 50.9 1.0
CD2 A:LEU640 4.7 51.2 1.0
CG1 A:ILE839 4.8 48.1 1.0
C5 A:KAV2501 4.9 51.6 1.0

Fluorine binding site 2 out of 6 in 6n3l

Go back to Fluorine Binding Sites List in 6n3l
Fluorine binding site 2 out of 6 in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 2 of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F2501

b:50.1
occ:1.00
F13 A:KAV2501 0.0 50.1 1.0
C11 A:KAV2501 1.3 47.0 1.0
F12 A:KAV2501 2.1 45.4 1.0
C8 A:KAV2501 2.2 51.0 1.0
F14 A:KAV2501 2.3 50.2 1.0
C9 A:KAV2501 2.5 47.1 1.0
C7 A:KAV2501 3.5 46.0 1.0
CD2 A:HIS846 3.5 49.1 1.0
CD1 A:ILE839 3.8 50.9 1.0
C10 A:KAV2501 3.9 49.4 1.0
CE A:MET844 4.0 57.9 1.0
CG A:HIS846 4.1 50.5 1.0
NE2 A:HIS846 4.2 48.6 1.0
CA A:HIS846 4.4 45.2 1.0
CB A:HIS846 4.4 47.0 1.0
C6 A:KAV2501 4.5 51.7 1.0
C5 A:KAV2501 4.7 51.6 1.0
ND1 A:HIS846 4.9 48.6 1.0
CG2 A:ILE864 5.0 40.1 1.0
CG1 A:ILE839 5.0 48.1 1.0
CE1 A:HIS846 5.0 55.2 1.0

Fluorine binding site 3 out of 6 in 6n3l

Go back to Fluorine Binding Sites List in 6n3l
Fluorine binding site 3 out of 6 in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 3 of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F2501

b:50.2
occ:1.00
F14 A:KAV2501 0.0 50.2 1.0
C11 A:KAV2501 1.4 47.0 1.0
F12 A:KAV2501 2.2 45.4 1.0
F13 A:KAV2501 2.3 50.1 1.0
C8 A:KAV2501 2.4 51.0 1.0
C7 A:KAV2501 2.8 46.0 1.0
CG2 A:ILE864 3.5 40.1 1.0
C9 A:KAV2501 3.6 47.1 1.0
CD1 A:ILE648 3.7 37.2 1.0
CD1 A:ILE839 3.8 50.9 1.0
O A:ILE864 3.8 40.4 1.0
CB A:ILE864 4.0 39.8 1.0
CD2 A:HIS846 4.0 49.1 1.0
CG2 A:ILE648 4.1 37.1 1.0
C6 A:KAV2501 4.1 51.7 1.0
C A:ILE864 4.2 39.4 1.0
CG2 A:ILE839 4.3 52.8 1.0
NE2 A:HIS846 4.5 48.6 1.0
N A:GLY865 4.7 43.0 1.0
CA A:ILE864 4.8 39.4 1.0
C10 A:KAV2501 4.8 49.4 1.0
CG1 A:ILE648 4.9 38.5 1.0
CA A:GLY865 4.9 42.6 1.0
O A:GLY865 5.0 42.5 1.0
CD1 A:LEU643 5.0 45.0 1.0
C5 A:KAV2501 5.0 51.6 1.0

Fluorine binding site 4 out of 6 in 6n3l

Go back to Fluorine Binding Sites List in 6n3l
Fluorine binding site 4 out of 6 in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 4 of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents within 5.0Å range:
probe atom residue distance (Å) B Occ
B:F2501

b:47.8
occ:1.00
F12 B:KAV2501 0.0 47.8 1.0
C11 B:KAV2501 1.4 47.9 1.0
F14 B:KAV2501 2.2 49.8 1.0
F13 B:KAV2501 2.3 41.1 1.0
C8 B:KAV2501 2.3 50.5 1.0
C7 B:KAV2501 2.9 47.5 1.0
CD1 B:LEU643 3.2 51.7 1.0
C9 B:KAV2501 3.4 50.2 1.0
CG2 B:ILE648 3.5 45.9 1.0
CG2 B:ILE839 3.7 53.2 1.0
CD1 B:ILE648 4.0 40.9 1.0
C6 B:KAV2501 4.1 48.5 1.0
CE B:MET844 4.2 64.8 1.0
CD1 B:ILE839 4.3 53.6 1.0
C10 B:KAV2501 4.6 50.5 1.0
CB B:ILE839 4.6 50.7 1.0
CG B:LEU643 4.6 54.4 1.0
CG1 B:ILE648 4.7 42.5 1.0
CB B:ILE648 4.7 42.7 1.0
CD2 B:LEU640 4.7 59.5 1.0
C5 B:KAV2501 4.9 51.2 1.0
SD B:MET844 5.0 66.2 1.0
O B:ILE864 5.0 40.3 1.0

Fluorine binding site 5 out of 6 in 6n3l

Go back to Fluorine Binding Sites List in 6n3l
Fluorine binding site 5 out of 6 in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 5 of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents within 5.0Å range:
probe atom residue distance (Å) B Occ
B:F2501

b:41.1
occ:1.00
F13 B:KAV2501 0.0 41.1 1.0
C11 B:KAV2501 1.4 47.9 1.0
F14 B:KAV2501 2.2 49.8 1.0
C8 B:KAV2501 2.2 50.5 1.0
F12 B:KAV2501 2.3 47.8 1.0
C9 B:KAV2501 2.5 50.2 1.0
CE B:MET844 3.4 64.8 1.0
C7 B:KAV2501 3.5 47.5 1.0
CD2 B:HIS846 3.8 42.2 1.0
C10 B:KAV2501 3.8 50.5 1.0
CD1 B:ILE839 3.9 53.6 1.0
CG B:HIS846 4.3 42.8 1.0
CA B:HIS846 4.5 42.0 1.0
NE2 B:HIS846 4.5 41.8 1.0
C6 B:KAV2501 4.6 48.5 1.0
CB B:HIS846 4.6 43.3 1.0
CD1 B:LEU643 4.7 51.7 1.0
C5 B:KAV2501 4.7 51.2 1.0
CG2 B:ILE839 4.7 53.2 1.0
SD B:MET844 4.9 66.2 1.0
CB B:ILE839 5.0 50.7 1.0
CG1 B:ILE839 5.0 51.3 1.0

Fluorine binding site 6 out of 6 in 6n3l

Go back to Fluorine Binding Sites List in 6n3l
Fluorine binding site 6 out of 6 in the Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 6 of Identification of Novel, Potent and Selective GCN2 Inhibitors As First-in-Class Anti-Tumor Agents within 5.0Å range:
probe atom residue distance (Å) B Occ
B:F2501

b:49.8
occ:1.00
F14 B:KAV2501 0.0 49.8 1.0
C11 B:KAV2501 1.4 47.9 1.0
F12 B:KAV2501 2.2 47.8 1.0
F13 B:KAV2501 2.2 41.1 1.0
C8 B:KAV2501 2.5 50.5 1.0
CD2 B:HIS846 3.2 42.2 1.0
C7 B:KAV2501 3.2 47.5 1.0
CG2 B:ILE864 3.4 42.3 1.0
C9 B:KAV2501 3.5 50.2 1.0
CD1 B:ILE839 3.6 53.6 1.0
NE2 B:HIS846 3.9 41.8 1.0
CB B:ILE864 4.1 44.6 1.0
CD1 B:ILE648 4.1 40.9 1.0
CG B:HIS846 4.2 42.8 1.0
O B:ILE864 4.3 40.3 1.0
CG2 B:ILE839 4.4 53.2 1.0
C B:ILE864 4.5 40.9 1.0
C6 B:KAV2501 4.5 48.5 1.0
CG2 B:ILE648 4.6 45.9 1.0
C10 B:KAV2501 4.7 50.5 1.0
CB B:HIS846 4.8 43.3 1.0
O B:GLY865 4.8 45.7 1.0
N B:GLY865 4.9 41.3 1.0
CG1 B:ILE839 4.9 51.3 1.0
CA B:ILE864 4.9 45.3 1.0
CA B:GLY865 5.0 44.0 1.0

Reference:

J.Fujimoto, O.Kurasawa, T.Takagi, X.Liu, H.Banno, T.Kojima, Y.Asano, A.Nakamura, T.Nambu, A.Hata, T.Ishii, T.Sameshima, Y.Debori, M.Miyamoto, M.G.Klein, R.Tjhen, B.C.Sang, I.Levin, S.W.Lane, G.P.Snell, K.Li, G.Kefala, I.D.Hoffman, S.C.Ding, D.R.Cary, R.Mizojiri. Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. Acs Med.Chem.Lett. V. 10 1498 2019.
ISSN: ISSN 1948-5875
PubMed: 31620240
DOI: 10.1021/ACSMEDCHEMLETT.9B00400
Page generated: Sun Dec 13 12:59:25 2020

Last articles

Zn in 8WB0
Zn in 8WAX
Zn in 8WAU
Zn in 8WAZ
Zn in 8WAY
Zn in 8WAV
Zn in 8WAW
Zn in 8WAT
Zn in 8W7M
Zn in 8WD3
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy